Entrada - TRDA EV/EBITDA Multiple

Corporate emblem and logo of Entrada (TRDA)

The historical share price analysis of Entrada Therapeutics (TRDA) on the GURU.Markets platform shows an EV/EBITDA ratio of 0.00. Entrada Therapeutics (TRDA) relies on a highly specialized protein delivery system to target muscle and nerve pathologies, mitigating high development risks through strategic alliances. Growth is driven by the success of the EEV method in treating Duchenne muscular dystrophy and payments from major pharmaceutical behemoths. This innovative approach enables the creation of medications for patients who previously lacked treatment options.

TRDA (Entrada) EV/EBITDA Multiple history from 11/23/2025 to 11/12/2026

TRDA (entradatx.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Entrada|TRDA - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Entrada Therapeutics, Inc|TRDA - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Entrada Therapeutics|TRDA - Book Capitalization|Market Value to Book Value Ratio entradatx.com|TRDA - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Entrada Therapeutics|TRDA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Entrada Therapeutics, Inc.|TRDA - Company Debts|Debt to Book Capitalization Ratio Entrada Therapeutics, Inc|TRDA - Long-Term Debt|Company Short-Term Debts Entrada Therapeutics|Quick Liquidity Indicator entradatx.com
- net income and valuation multiples indicators:
TRDA - Company Net Income|Projected Future Earnings Entrada Therapeutics|TRDA - Market Cap to Earnings|Future Price to Earnings Entrada Therapeutics|TRDA - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Entrada Therapeutics, Inc|TRDA - Company profit before taxes, interest and amortization|Earnings per share for the last twelve months Entrada Therapeutics|TRDA - Earnings per share for the trailing year|Quarterly EPS earnings growth entradatx.com|TRDA - Earnings growth in current year|Earnings growth forecast for next year Entrada Therapeutics
Summary company analytics:TRDA (Entrada)
Original product of Entrada Therapeutics, Inc.

Conservative capital demands maximum transparency of capital structure and operational business resilience. The EV/EBITDA multiple assesses the total enterprise value relative to its earnings before interest, taxes, depreciation, and amortization, excluding the impact of debt load. For Entrada Therapeutics (TRDA), amid fierce competition for neurology patents, this metric reveals the real value of assets. By analyzing the fluctuations in the company's EV/EBITDA level, an investor can determine the risk of overpaying for an overheated asset.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharma JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA scholarrock.com|CNTA (Centessa) - Enterprise Value to EBITDA Ratio|Dyne Therapeutics Inc (DYN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edgewise Pharma|RAPP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alumis Inc. (ALMS)|ZVRA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Contineum Therapeutics CTNM|Larimar Therapeutics Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CAPR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Channel Pharma|MNOV: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple serinatherapeutics.com SER|Enterprise Value to EBITDA Ratio BTAI|Company Value to EBITDA ProMIS PMN|EV/EBITDA Multiple APUS|AEON - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NLS Pharmaceutics NLSP|BNOX: Enterprise Value to Operating Income Before Depreciation|HUGE: Enterprise Value to EBITDA Ratio|Reata Pharmaceuticals Inc - Enterprise Value to Operating Income Before Depreciation Ratio